TOPICA Pharmaceuticals, Inc., a Palo Alto, CA-based clinical research stage pharmaceutical company, has raised $27m in a Series B funding.
The company intends to use the funds to advance its broad-spectrum topical antifungal agent, luliconazole, for the treatment of onychomycosis, fungal infections of the nail.
Led by president and CEO Greg Vontz, TOPICA plans to complete a Phase 2b/3 clinical trial of approximately 300 patients with mild-to-moderate distal subungual onychomycosis of the toenail. The trial will start in the first half of 2012 and will involve approximately 20 centers in the U.S.
In conjunction with the funding, Charles Homcy, M.D., venture partner at Third Rock Ventures, will join the company’s board of directors.